To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.
Xinhua Zhang,Ye Zhou,Xin Wu,Mingming Nie,Bo Zhang,Yongjian Zhou,Lifeng Sun,Xiufeng Liu,Zimin Liu,Youwei Kou,Yongpeng Wang,Yefan Zhang,Jian Li,Lin Shen
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.11530
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:11530 Background: Imatinib is recommended to treat gastrointestinal stromal tumor (GIST) receiving surgery after localized tumor progression, but the progression free survival (PFS) is not satisfied. The objective of this study is to investigate the optimal therapy after cytoreductive surgery in GIST patients with unifocal or multifocal progression on imatinib. Methods: The data of GIST patients who received R0 resection or satisfied cytoreductive surgery after unifocal or multifocal progression followed by different TKIs were collected. The satisfied cytoreductive surgery was defined as the diameter of every residual tumor was less than 1cm, or the proportion of residual tumor was less than 25% after cytoreductive surgery. The primary endpoint is to evaluate the PFS of the patients receiving surgery followed by sunitinib comparing with that of followed by imatinib after tumor progression. PFS curves were constructed according to the Kaplan–Meier method and compared using a log-rank test. Results: From January 2006 to June 2017, 97 patients from 13 medical centers were enrolled in this study. Fifty-six patients continued imatinib therapy and 41 patients switched to sunitinib directly after R0 resection or satisfied cytoreductive surgery. The PFS of sunitinib group was longer than that of imatinib group (30.0 months vs 12.0 months, p = 0.009). In subgroup analysis, the PFS of sunitinib group and imatinib group were 25.5 months and 12.0 months in patients with multifocal progression (p = 0.008), 39.0 months and 13.0 months with unifocal progression (p = 0.156), respectively. Patients carrying a primary KIT exon 11 mutation had a PFS of 31 months in sunitinib compared with 11 months in imatinib (p = 0.036), respectively. And those of KIT exon 9 mutation or KIT/PDGFRA wild-type had a PFS of 25.5 months to 13 months (p = 0.06), respectively. The overall survival in sunitinib group and imatinib group were 37.0 months and 33.0 months, respectively (p = 0.794). Conclusions: R0 or satisfied cytoreductive surgery followed by sunitinib treatment in GIST patients with progression on imatinib could improve PFS compared with surgery followed by imatinib therapy.